Santen Pharmaceutical Co., Ltd.

As of March 31, 2026, Santen Pharmaceutical Co., Ltd. carries a market capitalization of 574.36B, placing it among publicly traded companies globally. Its enterprise value stands at 490.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Santen Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 5, 2026.

As of March 31, 2026, Santen Pharmaceutical Co., Ltd. has 321.68M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Santen Pharmaceutical Co., Ltd. maintains a current ratio of 2.60, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Santen Pharmaceutical Co., Ltd.'s stock has gained approximately 13.33% over the past 52 weeks. The 50-day moving average sits at 1,788.09, while the 200-day moving average is 1,814.86.

These figures are as of March 31, 2026. Total book value stands at 296.99B, with working capital of 140.89B providing operational flexibility.

Santen Pharmaceutical Co., Ltd.'s most recent stock split took place on March 27, 2015 with a 1:5 split ratio.